Breaking News Instant updates and real-time market news.

BGAOY

Proximus

$3.51 /

+0.065 (+1.89%)

14:20
05/04/22
05/04
14:20
05/04/22
14:20

Proximus price target lowered to EUR 15.50 from EUR 17 at Barclays

Barclays analyst Mathieu Robilliard lowered the firm's price target on Proximus to EUR 15.50 from EUR 17 and keeps an Underweight rating on the shares.

OTHER BREAKING NEWS FROM THE FLY

Hot Stocks
Seagen announces results from pivotal MOUNTAINEER trial » 09:17
07/03/22
07/03
09:17
07/03/22
09:17
SGEN

Seagen

$180.09 /

+3.33 (+1.88%)

Seagen announced full…

Seagen announced full results from the pivotal phase 2 MOUNTAINEER trial, which showed TUKYSA in combination with trastuzumab was well-tolerated with durable responses in patients with previously treated HER2-positive metastatic colorectal cancer. These late-breaking data were presented in an oral session at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer on July 2 in Barcelona, Spain. At a median duration of follow-up of 20.7 months, results of the MOUNTAINEER trial showed a 38.1% confirmed objective response rate per blinded independent central review in the HER2-positive patients who were assigned to receive tucatinib in combination with trastuzumab. In these patients, the median duration of response per BICR was 12.4 months. Median progression-free survival per BICR was 8.2 months, and median overall survival was 24.1 months. At study entry, 64.3% and 70.2% of these patients had liver or lung metastases, respectively, and had received a median of 3.0 prior lines of systemic therapy. In a cohort of patients who received tucatinib monotherapy, the ORR per BICR by 12 weeks was 3.3% and the disease control rate was 80.0%. Participants who did not respond to tucatinib monotherapy by 12 weeks or progressed at any time had the option to receive the combination of tucatinib and trastuzumab. AEs leading to discontinuation of any treatment occurred in 5.8% of patients. No deaths due to AEs were reported. Data from this trial will form the basis of a planned supplemental New Drug Application to the U.S. Food and Drug Administration under the Accelerated Approval Program. Merck, known as MSD outside the U.S. and Canada, has exclusive rights to commercialize TUKYSA in regions outside of the U.S., Canada and Europe and plans to discuss these results with certain global health authorities.

ShowHide Related Items >><<
SGEN Seagen
$180.09 /

+3.33 (+1.88%)

SGEN Seagen
$180.09 /

+3.33 (+1.88%)

06/29/22 Raymond James
Seagen initiated with an Outperform at Raymond James
06/28/22 Piper Sandler
Sutro Biopharma price target raised to $16 from $14 at Piper Sandler
06/27/22 Cowen
Merck price target raised to $102 from $95 at Cowen
06/24/22 Mizuho
Merck deal would add 'novel and validated technology,' says Mizuho
SGEN Seagen
$180.09 /

+3.33 (+1.88%)

SGEN Seagen
$180.09 /

+3.33 (+1.88%)

SGEN Seagen
$180.09 /

+3.33 (+1.88%)

Upgrade
Techtronic upgraded to Buy from Neutral at Goldman Sachs » 08:42
07/03/22
07/03
08:42
07/03/22
08:42
TTNDY

Techtronic

$52.92 /

+0.57 (+1.09%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TTNDY Techtronic
$52.92 /

+0.57 (+1.09%)

04/14/22 Jefferies
Techtronic initiated with a Buy at Jefferies
02/07/22 Citi
Citi double downgrades Stanley Black & Decker on 2022 earnings risk
Initiation
HTC Corp. initiated with a Neutral at Goldman Sachs » 08:41
07/03/22
07/03
08:41
07/03/22
08:41
HTCKF

HTC Corp.

$6.50 /

+ (+0.00%)

Goldman Sachs analyst…

Goldman Sachs analyst Allen Chang initiated coverage of HTC Corp. with a Neutral rating and NT$76 price target. The analyst views HTC as a metaverse ecosystem play but says the earnings contributions remain at an early stage.

ShowHide Related Items >><<
HTCKF HTC Corp.
$6.50 /

+ (+0.00%)

05/04/22 Daiwa
HTC Corp. upgraded to Hold from Sell at Daiwa
Hot Stocks
Tesla reports Q2 deliveries of 254,695, says June highest production month » 13:23
07/02/22
07/02
13:23
07/02/22
13:23
TSLA

Tesla

$681.64 /

+8.33 (+1.24%)

Tesla reported Q2…

Tesla reported Q2 deliveries of 254,695, with 4% subject to operating lease accounting, and production of 258,580 vehicles. Tesla delivered 16,162 Model S/X and 238,533 Model 3/Y. The company said, "In the second quarter, we produced over 258,000 vehicles and delivered over 254,000 vehicles, despite ongoing supply chain challenges and factory shutdowns beyond our control. June 2022 was the highest vehicle production month in Tesla's history."

ShowHide Related Items >><<
TSLA Tesla
$681.64 /

+8.33 (+1.24%)

TSLA Tesla
$681.64 /

+8.33 (+1.24%)

06/30/22 Goldman Sachs
Tesla could net $3B by opening up charging network, says Goldman
06/30/22 Wedbush
Wedbush expects Tesla June delivery numbers to be ugly, focus on 2H trajectory
06/28/22 Deutsche Bank
Deutsche cuts Tesla target, estimates below consensus into delivery report
06/27/22 Mizuho
Tesla price target lowered to $1,150 from $1,300 at Mizuho
TSLA Tesla
$681.64 /

+8.33 (+1.24%)

TSLA Tesla
$681.64 /

+8.33 (+1.24%)

TSLA Tesla
$681.64 /

+8.33 (+1.24%)

TSLA Tesla
$681.64 /

+8.33 (+1.24%)

Periodicals
Not the time to bottom-fish cruise operator stocks, Barron's says » 09:54
07/02/22
07/02
09:54
07/02/22
09:54
CCL

Carnival

$8.82 /

+0.17 (+1.97%)

, NCLH

Norwegian Cruise Line

$11.35 /

+0.24 (+2.16%)

, RCL

Royal Caribbean

$35.30 /

+0.39 (+1.12%)

Shares of Carnival (CCL)…

Shares of Carnival (CCL) plunged 14% on Wednesday after a bearish research note by Morgan Stanley predicted the stock could fall to $0 in a worst-case scenario, Lawrence C. Strauss writes in this week's edition of Barron's. Rivals sank, too. Shares of Royal Caribbean (RCL) slid 10% that day, while Norwegian Cruise Line (NCLH) dropped 9%. The leverage buildup was crucial for the company's survival, but now rising interest rates make it a big headwind, as Carnival and its peers will have to refinance some of their debt in the next few years, the author notes. Reference Link

ShowHide Related Items >><<
RCL Royal Caribbean
$35.30 /

+0.39 (+1.12%)

NCLH Norwegian Cruise Line
$11.35 /

+0.24 (+2.16%)

CCL Carnival
$8.82 /

+0.17 (+1.97%)

CCL Carnival
$8.82 /

+0.17 (+1.97%)

06/29/22 Morgan Stanley
Morgan Stanley cuts Carnival price target to $7, sees bear case of zero
06/29/22 Barclays
Barclays initiates cruise line space with Royal Caribbean top pick
06/28/22 Barclays
Carnival initiated with an Overweight at Barclays
06/28/22 Citi
Carnival price target lowered to $12.50 from $22 at Citi
NCLH Norwegian Cruise Line
$11.35 /

+0.24 (+2.16%)

06/28/22 Barclays
Norwegian Cruise Line initiated with an Equal Weight at Barclays
06/21/22 Deutsche Bank
Norwegian Cruise Line price target lowered to $17 from $23 at Deutsche Bank
06/09/22 Susquehanna
Norwegian Cruise Line initiated with a Positive at Susquehanna
RCL Royal Caribbean
$35.30 /

+0.39 (+1.12%)

06/28/22 Barclays
Barclays says shift in preferences to cushion Gaming, Cruises, Timeshare names
06/28/22 Barclays
Royal Caribbean initiated with an Overweight at Barclays
06/21/22 Deutsche Bank
Royal Caribbean price target lowered to $50 from $76 at Deutsche Bank
RCL Royal Caribbean
$35.30 /

+0.39 (+1.12%)

NCLH Norwegian Cruise Line
$11.35 /

+0.24 (+2.16%)

CCL Carnival
$8.82 /

+0.17 (+1.97%)

RCL Royal Caribbean
$35.30 /

+0.39 (+1.12%)

NCLH Norwegian Cruise Line
$11.35 /

+0.24 (+2.16%)

CCL Carnival
$8.82 /

+0.17 (+1.97%)

RCL Royal Caribbean
$35.30 /

+0.39 (+1.12%)

NCLH Norwegian Cruise Line
$11.35 /

+0.24 (+2.16%)

CCL Carnival
$8.82 /

+0.17 (+1.97%)

RCL Royal Caribbean
$35.30 /

+0.39 (+1.12%)

NCLH Norwegian Cruise Line
$11.35 /

+0.24 (+2.16%)

CCL Carnival
$8.82 /

+0.17 (+1.97%)

Periodicals
Bed Bath & Beyond remodeling not working, Barron's says » 09:49
07/02/22
07/02
09:49
07/02/22
09:49
BBBY

Bed Bath & Beyond

$4.69 /

-0.27 (-5.44%)

, TGT

Target

$142.41 /

+1.27 (+0.90%)

No amount of activist…

No amount of activist activity has managed to fix what ails home-goods retailer Bed Bath & Beyond (BBBY) it seems, Carleton English writes in this week's edition of Barron's. Bed Bath & Beyond stock tumbled 34% last week after posting a wider-than-expected first-quarter loss. The company also announced the exit of CEO Mark Tritton, a former Target (TGT) executive who was installed at Bed Bath & Beyond three years ago with the support of activist investors. Bed Bath & Beyond has dealt with no fewer than four activists over the last three years. And just as changes appeared to gain momentum, the COVID-19 pandemic decimated bricks-and-mortar retail, and the company hasn't been able to regain its long-lost mojo, the author notes. Reference Link

ShowHide Related Items >><<
TGT Target
$142.41 /

+1.27 (+0.90%)

BBBY Bed Bath & Beyond
$4.69 /

-0.27 (-5.44%)

BBBY Bed Bath & Beyond
$4.69 /

-0.27 (-5.44%)

06/30/22 B. Riley
Bed Bath & Beyond price target lowered to $5 from $7 at B. Riley
06/30/22 Baird
Bed Bath & Beyond price target lowered to $4 from $7 at Baird
06/30/22 Loop Capital
Bed Bath & Beyond price target lowered to $1 from $5 at Loop Capital
06/30/22 Morgan Stanley
Bed Bath & Beyond price target lowered to $2 from $7 at Morgan Stanley
TGT Target
$142.41 /

+1.27 (+0.90%)

06/15/22 Credit Suisse
Ulta Beauty price target raised to $485 from $475 at Credit Suisse
06/10/22 Credit Suisse
Credit Suisse lowering EPS estimates for Target Corporation again
06/09/22 DA Davidson
Ulta Beauty price target raised to $490 from $465 at DA Davidson
06/09/22 Loop Capital
Loop Capital cuts Honest Company to Hold amid pressure reported in mass retail
TGT Target
$142.41 /

+1.27 (+0.90%)

BBBY Bed Bath & Beyond
$4.69 /

-0.27 (-5.44%)

TGT Target
$142.41 /

+1.27 (+0.90%)

BBBY Bed Bath & Beyond
$4.69 /

-0.27 (-5.44%)

TGT Target
$142.41 /

+1.27 (+0.90%)

BBBY Bed Bath & Beyond
$4.69 /

-0.27 (-5.44%)

TGT Target
$142.41 /

+1.27 (+0.90%)

BBBY Bed Bath & Beyond
$4.69 /

-0.27 (-5.44%)

Periodicals
AutoZone, O'Reilly among good buys in auto parts space, Barron's says » 09:37
07/02/22
07/02
09:37
07/02/22
09:37
AAP

Advance Auto Parts

$173.58 /

+1 (+0.58%)

, AZO

AutoZone

$2,160.68 /

+0.785 (+0.04%)

, GPC

Genuine Parts

$133.33 /

+0.39 (+0.29%)

, ORLY

O'Reilly Automotive

$636.18 /

+6.61 (+1.05%)

Auto parts retailers have…

Auto parts retailers have outpaced the market for much of the pandemic, and current economic uncertainty should keep the group in the fast lane, Teresa Rivas writes in this week's edition of Barron's. Auto parts retailers have a reputation as defensive stocks-after all, car repairs can only be delayed so long, even during a downturn. There are reasons to think the stocks can keep outperforming, the author says. The publication highlights that with the exception of Advance Auto Parts (AAP), retailers AutoZone (AZO), Genuine Parts (GPC) and O'Reilly Automotive (ORLY) have fared better than most in the current bear market. Reference Link

ShowHide Related Items >><<
ORLY O'Reilly Automotive
$636.18 /

+6.61 (+1.05%)

GPC Genuine Parts
$133.33 /

+0.39 (+0.29%)

AZO AutoZone
$2,160.68 /

+0.785 (+0.04%)

AAP Advance Auto Parts
$173.58 /

+1 (+0.58%)

AAP Advance Auto Parts
$173.58 /

+1 (+0.58%)

06/29/22 DA Davidson
O'Reilly Automotive upgraded to Buy from Neutral at DA Davidson
06/22/22 MKM Partners
Advance Auto Parts initiated with a Buy at MKM Partners
05/25/22 DA Davidson
Advance Auto Parts seeing signs of recovery, says DA Davidson
05/25/22 Raymond James
Advance Auto Parts price target lowered to $250 from $275 at Raymond James
AZO AutoZone
$2,160.68 /

+0.785 (+0.04%)

06/27/22 Goldman Sachs
AutoZone upgraded to Buy from Neutral at Goldman Sachs
06/23/22 Citi
Citi adds AutoZone, Thermo Fisher, Ionis to 'Focus List'
06/22/22 MKM Partners
AutoZone initiated with a Buy at MKM Partners
GPC Genuine Parts
$133.33 /

+0.39 (+0.29%)

05/10/22 BofA
Genuine Parts upgraded to Neutral at BofA on valuation
05/10/22 BofA
Genuine Parts upgraded to Neutral from Underperform at BofA
04/20/22 Evercore ISI
Genuine Parts added to 'Tactical Outperform' list at Evercore ISI
01/12/22 Truist
Truist starts Genuine Parts with Hold, says cautious on lower auto part growth
ORLY O'Reilly Automotive
$636.18 /

+6.61 (+1.05%)

06/22/22 MKM Partners
O'Reilly Automotive initiated with a Buy at MKM Partners
05/13/22 Citi
O'Reilly Automotive price target lowered to $662 from $720 at Citi
05/10/22 BofA
O'Reilly Automotive upgraded to Buy at BofA, price target unchanged at $730
ORLY O'Reilly Automotive
$636.18 /

+6.61 (+1.05%)

GPC Genuine Parts
$133.33 /

+0.39 (+0.29%)

AZO AutoZone
$2,160.68 /

+0.785 (+0.04%)

AAP Advance Auto Parts
$173.58 /

+1 (+0.58%)

GPC Genuine Parts
$133.33 /

+0.39 (+0.29%)

AZO AutoZone
$2,160.68 /

+0.785 (+0.04%)

ORLY O'Reilly Automotive
$636.18 /

+6.61 (+1.05%)

GPC Genuine Parts
$133.33 /

+0.39 (+0.29%)

AZO AutoZone
$2,160.68 /

+0.785 (+0.04%)

AAP Advance Auto Parts
$173.58 /

+1 (+0.58%)

ORLY O'Reilly Automotive
$636.18 /

+6.61 (+1.05%)

AAP Advance Auto Parts
$173.58 /

+1 (+0.58%)

Periodicals
Las Vegas Sands could win big as China eases COVID rules, Barron's says » 09:30
07/02/22
07/02
09:30
07/02/22
09:30
LVS

Las Vegas Sands

$35.28 /

+1.67 (+4.97%)

China's decision to…

China's decision to ease its entry requirements for international travelers is a step toward a fuller reopening and away from a zero-COVID strategy. It also signals an eventual reopening of its Macau casinos, Teresa Rivas writes in this week's edition of Barron's. It may be the right time to bet on Las Vegas Sands, the author says. Las Vegas Sands gets a little over two-thirds of its business from Macau, with the remainder coming from its Marina Bay Sands property in Singapore. The latter is an underappreciated asset that provides earnings visibility, while the former could see profits jump when Macau more fully reopens, following in the footsteps of Las Vegas and other U.S. cities, where gross gaming revenue has exploded above prepandemic levels, Rivas adds. Reference Link

ShowHide Related Items >><<
LVS Las Vegas Sands
$35.28 /

+1.67 (+4.97%)

LVS Las Vegas Sands
$35.28 /

+1.67 (+4.97%)

06/29/22 Barclays
Barclays initiates gaming sector, says Caesars best positioned
06/28/22 Barclays
Barclays says shift in preferences to cushion Gaming, Cruises, Timeshare names
06/28/22 Barclays
Las Vegas Sands initiated with an Overweight at Barclays
04/28/22 Stifel
Las Vegas Sands price target lowered to $46 from $56 at Stifel
LVS Las Vegas Sands
$35.28 /

+1.67 (+4.97%)

LVS Las Vegas Sands
$35.28 /

+1.67 (+4.97%)

LVS Las Vegas Sands
$35.28 /

+1.67 (+4.97%)

LVS Las Vegas Sands
$35.28 /

+1.67 (+4.97%)

Periodicals
Activision stock is a bet worth making on Microsoft's takeover, Barron's says » 09:28
07/02/22
07/02
09:28
07/02/22
09:28
MSFT

Microsoft

$259.51 /

+2.5 (+0.97%)

, ATVI

Activision Blizzard

$78.53 /

+0.71 (+0.91%)

With mergers getting…

With mergers getting increased scrutiny, Microsoft (MSFT) picked a tough time to buy Activision Blizzard (ATVI). But the regulatory uncertainty might give investors an opportunity for some easy upside in the gaming company's stock, Connor Smith writes in this week's edition of Barron's. Activision disclosed in March that it and Microsoft received a second request for information, which requires companies to turn over documents and answer business questions. The author believes, however, that the antitrust concerns seem overblown. Reference Link

ShowHide Related Items >><<
MSFT Microsoft
$259.51 /

+2.5 (+0.97%)

ATVI Activision Blizzard
$78.53 /

+0.71 (+0.91%)

MSFT Microsoft
$259.51 /

+2.5 (+0.97%)

06/29/22 Redburn
Microsoft initiated with a Buy at Redburn
06/27/22 William Blair
Okta not seeing backlash from security breach, says William Blair
06/24/22 Citi
Citi names top software picks with sector de-rating 'mostly done'
06/17/22 Morgan Stanley
Microsoft gaming build out hitting 'overdrive,' says Morgan Stanley
ATVI Activision Blizzard
$78.53 /

+0.71 (+0.91%)

05/31/22 Benchmark
Marcus, Imax, WWE added to entertainment top ideas list at Benchmark
05/06/22 Benchmark
Playstudios could still be target as industry consolidates, says Benchmark
04/25/22 Benchmark
Activision results for Blizzard 'somewhat shocking,' says Benchmark
04/19/22 Goldman Sachs
Activision Blizzard assumed with Not Rated at Goldman Sachs
MSFT Microsoft
$259.51 /

+2.5 (+0.97%)

ATVI Activision Blizzard
$78.53 /

+0.71 (+0.91%)

MSFT Microsoft
$259.51 /

+2.5 (+0.97%)

ATVI Activision Blizzard
$78.53 /

+0.71 (+0.91%)

MSFT Microsoft
$259.51 /

+2.5 (+0.97%)

ATVI Activision Blizzard
$78.53 /

+0.71 (+0.91%)

MSFT Microsoft
$259.51 /

+2.5 (+0.97%)

ATVI Activision Blizzard
$78.53 /

+0.71 (+0.91%)

On The Fly
Opening Day: Ivanhoe Electric falls in debut after raising $169M in IPO » 09:10
07/02/22
07/02
09:10
07/02/22
09:10
GS

Goldman Sachs

$299.19 /

+1.98 (+0.67%)

, IE

Ivanhoe Electric

$9.00 /

+0.29 (+3.33%)

, PEV

Phoenix Motor

$4.69 /

+0.04 (+0.86%)

, REBN

Reborn Coffee

/

+

, SEAC

SeaChange

/

+

, JPM

JPMorgan

$114.11 /

+1.42 (+1.26%)

, AMZN

Amazon.com

$109.60 /

+3.3 (+3.10%)

, UBER

Uber

$21.34 /

+0.895 (+4.38%)

, DASH

DoorDash

$67.90 /

+3.71 (+5.78%)

, BITD

Bitdefender

/

+

Shares of Ivanhoe…

ShowHide Related Items >><<
UBER Uber
$21.34 /

+0.895 (+4.38%)

SEAC SeaChange
/

+

PEV Phoenix Motor
$4.69 /

+0.04 (+0.86%)

JPM JPMorgan
$114.11 /

+1.42 (+1.26%)

GS Goldman Sachs
$299.19 /

+1.98 (+0.67%)

DASH DoorDash
$67.90 /

+3.71 (+5.78%)

AMZN Amazon.com
$109.60 /

+3.3 (+3.10%)

GS Goldman Sachs
$299.19 /

+1.98 (+0.67%)

07/01/22 RBC Capital
Goldman Sachs price target lowered to $370 from $390 at RBC Capital
07/01/22 Oppenheimer
Oppenheimer says U.S. financial institutions 'dramatically undervalued'
07/01/22 Piper Sandler
Goldman Sachs price target lowered to $410 from $430 at Piper Sandler
06/29/22 BofA
Goldman Sachs upgraded to Buy from Neutral at BofA
IE Ivanhoe Electric
$9.00 /

+0.29 (+3.33%)

PEV Phoenix Motor
$4.69 /

+0.04 (+0.86%)

REBN Reborn Coffee
/

+

SEAC SeaChange
/

+

JPM JPMorgan
$114.11 /

+1.42 (+1.26%)

07/01/22 Piper Sandler
JPMorgan price target lowered to $158 from $170 at Piper Sandler
06/24/22 Morgan Stanley
JPMorgan price target lowered to $149 from $152 at Morgan Stanley
05/24/22 Societe Generale
Societe Generale upgrades JPMorgan with $150 target after investor day
AMZN Amazon.com
$109.60 /

+3.3 (+3.10%)

06/29/22 JPMorgan
Amazon.com price target lowered to $175 from $200 at JPMorgan
06/29/22 Redburn
Microsoft initiated with a Buy at Redburn
06/29/22 Redburn
Amazon.com initiated with a Buy at Redburn
06/29/22 Wolfe Research
Amazon.com price target lowered to $140 from $145 at Wolfe Research
UBER Uber
$21.34 /

+0.895 (+4.38%)

06/29/22 JPMorgan
Uber price target lowered to $48 from $60 at JPMorgan
06/29/22 Wedbush
Uber assumed with an Outperform at Wedbush
06/24/22 Wolfe Research
Uber price target lowered to $27 from $30 at Wolfe Research
06/16/22 Mizuho
Uber hits 'speed bump' in Massachusetts, says Mizuho
DASH DoorDash
$67.90 /

+3.71 (+5.78%)

06/29/22 JPMorgan
DoorDash price target lowered to $90 from $100 at JPMorgan
06/27/22 Needham
DoorDash price target lowered to $100 from $140 at Needham
06/21/22 Goldman Sachs
DoorDash reinstated with a Neutral at Goldman Sachs
06/06/22 Raymond James
DoorDash initiated with a Market Perform at Raymond James
BITD Bitdefender
/

+

UBER Uber
$21.34 /

+0.895 (+4.38%)

SEAC SeaChange
/

+

JPM JPMorgan
$114.11 /

+1.42 (+1.26%)

GS Goldman Sachs
$299.19 /

+1.98 (+0.67%)

DASH DoorDash
$67.90 /

+3.71 (+5.78%)

AMZN Amazon.com
$109.60 /

+3.3 (+3.10%)

  • 28
    Jun
  • 08
    Jun
  • 19
    Aug
  • 29
    Jul
UBER Uber
$21.34 /

+0.895 (+4.38%)

JPM JPMorgan
$114.11 /

+1.42 (+1.26%)

GS Goldman Sachs
$299.19 /

+1.98 (+0.67%)

DASH DoorDash
$67.90 /

+3.71 (+5.78%)

AMZN Amazon.com
$109.60 /

+3.3 (+3.10%)

UBER Uber
$21.34 /

+0.895 (+4.38%)

PEV Phoenix Motor
$4.69 /

+0.04 (+0.86%)

JPM JPMorgan
$114.11 /

+1.42 (+1.26%)

IE Ivanhoe Electric
$9.00 /

+0.29 (+3.33%)

GS Goldman Sachs
$299.19 /

+1.98 (+0.67%)

DASH DoorDash
$67.90 /

+3.71 (+5.78%)

BITD Bitdefender
/

+

AMZN Amazon.com
$109.60 /

+3.3 (+3.10%)

UBER Uber
$21.34 /

+0.895 (+4.38%)

SEAC SeaChange
/

+

JPM JPMorgan
$114.11 /

+1.42 (+1.26%)

GS Goldman Sachs
$299.19 /

+1.98 (+0.67%)

DASH DoorDash
$67.90 /

+3.71 (+5.78%)

AMZN Amazon.com
$109.60 /

+3.3 (+3.10%)

Hot Stocks
Seagen says Tukysa combo shows clinically meaningful antitumor activity in trial » 08:41
07/02/22
07/02
08:41
07/02/22
08:41
SGEN

Seagen

$180.09 /

+3.33 (+1.88%)

, MRK

Merck

$92.39 /

+1.06 (+1.16%)

Seagen (SGEN) announced…

Seagen (SGEN) announced full results from the pivotal phase 2 MOUNTAINEER trial, which showed TUKYSA in combination with trastuzumab was well-tolerated with durable responses in patients with previously treated HER2-positive metastatic colorectal cancer, or mCRC. These late-breaking data were presented in an oral session at the European Society for Medical Oncology, or ESMO, World Congress on Gastrointestinal Cancer on July 2 in Barcelona, Spain. At a median duration of follow-up of 20.7 months, results of the MOUNTAINEER trial showed a 38.1% confirmed objective response rate, or cORR, per blinded independent central review in the HER2-positive patients who were assigned to receive tucatinib in combination with trastuzumab. In these patients, the median duration of response, or DoR, per BICR was 12.4 months. Median progression-free survival per BICR was 8.2 months and median overall survival was 24.1 months. At study entry, 64.3% and 70.2% of these patients had liver or lung metastases, respectively, and had received a median of 3.0 prior lines of systemic therapy. In a cohort of patients who received tucatinib monotherapy, the ORR per BICR by 12 weeks was 3.3% and the disease control rate was 80.0%. Participants who did not respond to tucatinib monotherapy by 12 weeks or progressed at any time had the option to receive the combination of tucatinib and trastuzumab. Data from this trial will form the basis of a planned supplemental New Drug Application to the U.S. Food and Drug Administration under the Accelerated Approval Program. Merck (MRK) has exclusive rights to commercialize TUKYSA in regions outside of the U.S., Canada and Europe and plans to discuss these results with certain global health authorities. "This study has shown the benefits of dual-HER2 inhibition with tucatinib and trastuzumab in patients with HER2-positive metastatic colorectal cancer, including many whose cancer had spread to the liver or lungs before joining the trial. We believe this chemotherapy-free combination may play an important role in addressing the unmet needs of patients with this disease," said Roger Dansey, M.D., interim CEO and Chief Medical Officer, Seagen.

ShowHide Related Items >><<
SGEN Seagen
$180.09 /

+3.33 (+1.88%)

MRK Merck
$92.39 /

+1.06 (+1.16%)

SGEN Seagen
$180.09 /

+3.33 (+1.88%)

06/29/22 Raymond James
Seagen initiated with an Outperform at Raymond James
06/28/22 Piper Sandler
Sutro Biopharma price target raised to $16 from $14 at Piper Sandler
06/27/22 Cowen
Merck price target raised to $102 from $95 at Cowen
06/24/22 Mizuho
Merck deal would add 'novel and validated technology,' says Mizuho
MRK Merck
$92.39 /

+1.06 (+1.16%)

SGEN Seagen
$180.09 /

+3.33 (+1.88%)

MRK Merck
$92.39 /

+1.06 (+1.16%)

SGEN Seagen
$180.09 /

+3.33 (+1.88%)

MRK Merck
$92.39 /

+1.06 (+1.16%)

SGEN Seagen
$180.09 /

+3.33 (+1.88%)

MRK Merck
$92.39 /

+1.06 (+1.16%)

Hot Stocks
Trump Media & Technology Group says 'expanding and enhancing Truth Social' » 18:54
07/01/22
07/01
18:54
07/01/22
18:54
DWAC

Digital World Acquisition

$24.12 /

-0.08 (-0.33%)

Trump Media &…

Trump Media & Technology Group issued the following statement: "TMTG is expanding and enhancing Truth Social, with a major update to the platform scheduled for next week. TMTG will continue cooperating fully with inquiries into our planned merger and will comply with subpoenas we've recently received, none of which were directed at the company's Chairman or CEO."

ShowHide Related Items >><<
DWAC Digital World Acquisition
$24.12 /

-0.08 (-0.33%)

DWAC Digital World Acquisition
$24.12 /

-0.08 (-0.33%)

DWAC Digital World Acquisition
$24.12 /

-0.08 (-0.33%)

DWAC Digital World Acquisition
$24.12 /

-0.08 (-0.33%)

Hot Stocks
Macerich president Coppola acquires 60,000 common shares » 17:48
07/01/22
07/01
17:48
07/01/22
17:48
MAC

Macerich

$8.93 /

+0.23 (+2.64%)

In a regulatory filing,…

In a regulatory filing, Macerich president Edward Coppola disclosed the purchase of 60,000 common shares of the company on June 30 at a price of $8.75 per share.

ShowHide Related Items >><<
MAC Macerich
$8.93 /

+0.23 (+2.64%)

MAC Macerich
$8.93 /

+0.23 (+2.64%)

06/30/22 Jefferies
Macerich price target lowered to $9 from $15 at Jefferies
06/22/22 Compass Point
Macerich price target lowered to $20 from $27 at Compass Point
06/21/22 Truist
Macerich price target lowered to $14 from $18 at Truist
04/18/22 Piper Sandler
Macerich downgraded to Underweight from Neutral at Piper Sandler
MAC Macerich
$8.93 /

+0.23 (+2.64%)

Hot Stocks
MAK Capital One reports 19.4% stake in Yatra » 17:41
07/01/22
07/01
17:41
07/01/22
17:41
YTRA

Yatra

$2.37 /

+0.115 (+5.10%)

MAK Capital One changed…

MAK Capital One changed its filing status to active from passive and intends to engage directly with Yatra.

ShowHide Related Items >><<
YTRA Yatra
$2.37 /

+0.115 (+5.10%)

Syndicate
Ondas files to sell 780,000 shares of common stock for holders  17:25
07/01/22
07/01
17:25
07/01/22
17:25
ONDS

Ondas

$5.50 /

+0.12 (+2.23%)

 
ShowHide Related Items >><<
ONDS Ondas
$5.50 /

+0.12 (+2.23%)

ONDS Ondas
$5.50 /

+0.12 (+2.23%)

Syndicate
SpringBig files to sell 4.51M shares of common stock for holders  17:24
07/01/22
07/01
17:24
07/01/22
17:24
SBIG

SpringBig

$2.06 /

+0.25 (+13.81%)

 
ShowHide Related Items >><<
SBIG SpringBig
$2.06 /

+0.25 (+13.81%)

SBIG SpringBig
$2.06 /

+0.25 (+13.81%)

06/24/22 Jefferies
SpringBig initiated with a Buy at Jefferies
06/24/22 Jefferies
SpringBig initiated with a Buy at Jefferies
Hot Stocks
Northrop Grumman awarded $337.94M Navy contract » 17:23
07/01/22
07/01
17:23
07/01/22
17:23
NOC

Northrop Grumman

$486.34 /

+9.26 (+1.94%)

Northrop Grumman was…

Northrop Grumman was awarded a $337.94M cost-plus-fixed-fee, firm-fixed-price and cost reimbursable indefinite-delivery/indefinite-quantity contract. This contract provides researching alternatives, investigating and documenting new capabilities and anomalies related to H-1 avionics and weapons; and the development, integration, verification, validation, and testing of H-1 Integrated Avionics Systems, as well as identifies maintenance capabilities, upgrading and/or updating test equipment and other support equipment required to support the systems. Work is expected to be completed in June 2027. No funds will be obligated at the time of award; funds will be obligated on individual orders as they are issued. This contract was not competitively procured pursuant to Defense Federal Acquisition Regulation 6.302-1. The Naval Air Warfare Center Weapons Division is the contracting activity.

ShowHide Related Items >><<
NOC Northrop Grumman
$486.34 /

+9.26 (+1.94%)

NOC Northrop Grumman
$486.34 /

+9.26 (+1.94%)

05/12/22 Argus
Northrop Grumman price target raised to $495 from $420 at Argus
04/29/22 UBS
Northrop Grumman price target raised to $450 from $410 at UBS
03/29/22 Jefferies
Northrop among biggest beneficiaries of DoD budget request, says Jefferies
03/07/22 Wells Fargo
Northrop Grumman price target raised to $472 from $390 at Wells Fargo
NOC Northrop Grumman
$486.34 /

+9.26 (+1.94%)

NOC Northrop Grumman
$486.34 /

+9.26 (+1.94%)

NOC Northrop Grumman
$486.34 /

+9.26 (+1.94%)

NOC Northrop Grumman
$486.34 /

+9.26 (+1.94%)

Syndicate
Jakks Pacific files to sell 2M shares of common stock  17:19
07/01/22
07/01
17:19
07/01/22
17:19
JAKK

Jakks Pacific

$13.19 /

+0.72 (+5.77%)

 
ShowHide Related Items >><<
JAKK Jakks Pacific
$13.19 /

+0.72 (+5.77%)

JAKK Jakks Pacific
$13.19 /

+0.72 (+5.77%)

05/03/22 BMO Capital
Jakks Pacific upgraded to Outperform at BMO Capital on more encouraging trends
05/03/22 BMO Capital
Jakks Pacific upgraded to Outperform from Market Perform at BMO Capital
02/22/22 BMO Capital
JAKKS Pacific price target raised to $15 from $12 at BMO Capital
07/23/21 BMO Capital
BMO 'increasingly more concerned' about guidance from toy companies
JAKK Jakks Pacific
$13.19 /

+0.72 (+5.77%)

JAKK Jakks Pacific
$13.19 /

+0.72 (+5.77%)

Syndicate
Creatd files to sell 6M shares of common stock for holders  17:19
07/01/22
07/01
17:19
07/01/22
17:19
CRTD

Creatd

/

+

 
ShowHide Related Items >><<
CRTD Creatd
/

+

CRTD Creatd
/

+

Hot Stocks
AT&T names Debra Dial as SVP, Chief Accounting Officer and Controller » 17:18
07/01/22
07/01
17:18
07/01/22
17:18
T

AT&T

$21.32 /

+0.345 (+1.65%)

On June 30, AT&T…

On June 30, AT&T appointed Debra Dial to the position of Senior Vice President - Chief Accounting Officer and Controller, and Dial assumed the responsibilities of principal accounting officer. Dial has served in various positions with the company for 25 years, including as Senior Vice President - Controller for the last six years. The designation as the principal accounting officer recognizes her responsibilities as Chief Accounting Officer and conforms to prevalent industry practice. Pascal Desroches, the company's Senior Executive Vice President and CFO, acted as the company's principal accounting officer prior to Dial's appointment.

ShowHide Related Items >><<
T AT&T
$21.32 /

+0.345 (+1.65%)

T AT&T
$21.32 /

+0.345 (+1.65%)

06/28/22 Scotiabank
AT&T assumed with a Sector Perform at Scotiabank (yesterday)
06/16/22 Tigress Financial
AT&T price target lowered to $28 from $31 at Tigress Financial
06/02/22 Wolfe Research
AT&T price target lowered to $22 from $27 at Wolfe Research
05/31/22 LightShed Partners
Verizon initiated with a Neutral at LightShed Partners
T AT&T
$21.32 /

+0.345 (+1.65%)

T AT&T
$21.32 /

+0.345 (+1.65%)

T AT&T
$21.32 /

+0.345 (+1.65%)

T AT&T
$21.32 /

+0.345 (+1.65%)

Periodicals
TC Energy agrees with Mexico to construct $5B gas pipeline, Reuters says » 17:14
07/01/22
07/01
17:14
07/01/22
17:14
TRP

TC Energy

$52.62 /

+0.835 (+1.61%)

Mexico senior foreign…

Mexico senior foreign ministry official Roberto Velasco said that Canada's TC Energy has struck an agreement with Mexico to construct a $5B gas pipeline in the Mexican Gulf Coast state of Veracruz, Reuters' Dave Graham reports. The pipeline will connect the Tuxpan and Caotzacoalcos ports, the author says, citing a separate source familiar with the matter. Reference Link

ShowHide Related Items >><<
TRP TC Energy
$52.62 /

+0.835 (+1.61%)

TRP TC Energy
$52.62 /

+0.835 (+1.61%)

05/12/22 CIBC
TC Energy upgraded to Outperformer from Neutral at CIBC
04/26/22 Morgan Stanley
TC Energy downgraded to Underweight at Morgan Stanley on valuation
04/26/22 Morgan Stanley
TC Energy downgraded to Underweight from Equal Weight at Morgan Stanley
04/13/22 Scotiabank
TC Energy price target raised to C$78 from C$72 at Scotiabank
TRP TC Energy
$52.62 /

+0.835 (+1.61%)

TRP TC Energy
$52.62 /

+0.835 (+1.61%)

Syndicate
Acumen files $200M mixed securities shelf  17:08
07/01/22
07/01
17:08
07/01/22
17:08
ABOS

Acumen

$4.72 /

+0.02 (+0.43%)

 
ShowHide Related Items >><<
ABOS Acumen
$4.72 /

+0.02 (+0.43%)

ABOS Acumen
$4.72 /

+0.02 (+0.43%)

06/30/22 H.C. Wainwright
Acumen initiated with a Buy at H.C. Wainwright
03/29/22 Credit Suisse
Acumen price target lowered to $17 from $26 at Credit Suisse
01/21/22 BofA
Acumen upgraded to Buy following recent selloff at BofA
01/21/22 BofA
Acumen upgraded to Buy from Neutral at BofA
ABOS Acumen
$4.72 /

+0.02 (+0.43%)

Hot Stocks
Sanofi flu vaccines licensed, approved for 2022-2023 influenza season » 17:07
07/01/22
07/01
17:07
07/01/22
17:07
SNY

Sanofi

$50.91 /

+0.95 (+1.90%)

The U.S. FDA approved…

The U.S. FDA approved Sanofi's licensure request for vaccine approval for the upcoming 2022-2023 flu season, including: Fluzone High-Dose Quadrivalent (Influenza Vaccine), Flublok Quadrivalent (Influenza Vaccine) and Fluzone Quadrivalent (Influenza Vaccine). This approval comes on the heels of the CDC's Advisory Committee on Immunization Practices preferential recommendation for adults 65+ including Fluzone High-Dose Quadrivalent and Flublok Quadrivalent. Following this licensure, Sanofi will begin to ship their vaccines helping to ensure more people, including some of our most vulnerable population of 65 years and older, will be immunized with the vaccine best suited for their needs as recommended by the ACIP.

ShowHide Related Items >><<
SNY Sanofi
$50.91 /

+0.95 (+1.90%)

SNY Sanofi
$50.91 /

+0.95 (+1.90%)

06/07/22 UBS
Sanofi price target raised to EUR 119 from EUR 118 at UBS
06/02/22 Piper Sandler
Regeneron selloff on Libtayo deal overdone, says Piper Sandler
06/01/22 Wells Fargo
Kymera Therapeutics price target lowered to $35 from $62 at Wells Fargo
05/23/22 SVB Securities
Sanofi initiated with an Outperform at SVB Leerink
SNY Sanofi
$50.91 /

+0.95 (+1.90%)

SNY Sanofi
$50.91 /

+0.95 (+1.90%)

SNY Sanofi
$50.91 /

+0.95 (+1.90%)

Syndicate
Monte Rosa Therapeutics files $300M mixed securities shelf  17:04
07/01/22
07/01
17:04
07/01/22
17:04
GLUE

Monte Rosa Therapeutics

$10.10 /

+0.31 (+3.17%)

 
ShowHide Related Items >><<
GLUE Monte Rosa Therapeutics
$10.10 /

+0.31 (+3.17%)

GLUE Monte Rosa Therapeutics
$10.10 /

+0.31 (+3.17%)

05/11/22 Piper Sandler
Monte Rosa Therapeutics price target lowered to $21 from $40 at Piper Sandler
04/28/22 Credit Suisse
Monte Rosa Therapeutics initiated with a Neutral at Credit Suisse
04/08/22 Piper Sandler
Piper keeps Overweight rating on Monte Rosa Therapeutics after AACR abstract
02/09/22 Wells Fargo
Wells Fargo starts Monte Rosa Therapeutics at Equal Weight, sees few catalysts
GLUE Monte Rosa Therapeutics
$10.10 /

+0.31 (+3.17%)

GLUE Monte Rosa Therapeutics
$10.10 /

+0.31 (+3.17%)

GLUE Monte Rosa Therapeutics
$10.10 /

+0.31 (+3.17%)

Syndicate
TOP Ships files to sell 14.3M shares of common stock for holders  17:03
07/01/22
07/01
17:03
07/01/22
17:03
TOPS

TOP Ships

/

+

 
ShowHide Related Items >><<
TOPS TOP Ships
/

+

TOPS TOP Ships
/

+

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.